{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:06:53Z","timestamp":1758672413261,"version":"3.44.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"Background<\/jats:title>The IMforte trial demonstrated that lurbinectedin combined with atezolizumab (LU-AT) as a first-line regimen offers clinical advantages over atezolizumab alone (AT) in patients with extensive-stage small-cell lung cancer (ES-SCLC). However, given the high costs of lurbinectedin and atezolizumab, the cost-effectiveness of LU-AT relative to AT remains uncertain. This study aims to assess the cost-effectiveness of LU-AT as a first-line treatment for ES-SCLC within the context of China\u2019s and the United States\u2019 healthcare system.<\/jats:p><\/jats:sec>Methods<\/jats:title>A partitioned survival analysis (PartSA) model was employed to assess the cost-effectiveness of LU-AT as a first-line treatment for ES-SCLC. Clinical efficacy data were sourced from the IMforte trial. Drug costs were based on national tender prices, while other costs and utility values were derived from the literature. Outcomes included total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the robustness of the model.<\/jats:p><\/jats:sec>Results<\/jats:title>The combination regimen of lurbinectedin plus atezolizumab yielded an additional 0.21 QALYs compared with atezolizumab monotherapy, leading to an ICER of $374,167.43 per QALY in China and $1,071,237.82 per QALY in the USA, both beyond the willing-to-pay threshold ($40,365.00\/QALY in China and $150,000.00\/QALY in the USA). The utility of progression-free survival (PFS), the cost of lurbinectedin, body surface area (BSA), and the cost of atezolizumab are the four most influential factors in both China and the United States. Across all sensitivity analyses, the outcomes generated by the models remained robust. At a willingness-to-pay threshold of $40,365 and $150,000 per QALY, the probability of LU-AT being cost-effective relative to AT was 0% in China and USA.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Within the framework of China\u2019s and the United States\u2019 healthcare system, LU-AT is unlikely to represent a cost-effective first-line treatment for ES-SCLC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1658740","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:30:36Z","timestamp":1758605436000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yufan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00992-5","article-title":"The current and emerging immunotherapy paradigm in small-cell lung cancer","volume":"6","author":"Qin","year":"2025","journal-title":"Nat Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1477146","article-title":"Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer","volume":"15","author":"You","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-021-00486-y","article-title":"Update 2021: management of small cell lung cancer","volume":"199","author":"Tariq","year":"2021","journal-title":"Lung"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","volume-title":"Guidelines of Chinese society of clinical oncology (CSCO) for small-cell lung cancer","year":"2024"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.650392","article-title":"Economic evaluation of first-line atezolizumab for extensive-stage small-cell lung cancer in the US","volume":"9","author":"Wang","year":"2021","journal-title":"Front Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408928","article-title":"First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis","volume":"15","author":"Yi","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7796","article-title":"Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer","volume":"19","author":"Ding","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1241130","article-title":"Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing","volume":"14","author":"Gan","year":"2023","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01968-2","article-title":"Cost-effectiveness of benmelstobart-anlotinib-chemotherapy in extensive-stage small-cell lung cancer: A comparative analysis across United States and Chinese healthcare systems","author":"Wan","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1156427","article-title":"Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer","volume":"11","author":"Liang","year":"2023","journal-title":"Front Public Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br J Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1013-5","article-title":"Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis","volume":"15","author":"Song","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1575627","article-title":"Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0064-3","article-title":"Overview of parametric survival analysis for health-economic applications","volume":"31","author":"Ishak","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: A comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"key":"B24","unstructured":"Yao\n ZH\n \n \n The big data service platform for China\u2019s health industry: Information Query of Drug Bid Winning"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1556100","article-title":"Cost-effectiveness analysis of Toripalimab regimen for extensive-stage small-cell lung cancer in China and America","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B26","unstructured":""},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602185","article-title":"First-line durvalumab plus platinum-etoposide versus platinum-etoposide for extensive-stage small-cell lung cancer: A cost-effectiveness analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00586-6","article-title":"Serplulimab plus chemotherapy vs chemotherapy for treatment of US and chinese patients with extensive-stage small-cell lung cancer: A cost-effectiveness analysis to inform drug pricing","volume":"37","author":"Shao","year":"2023","journal-title":"BioDrugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1349645","article-title":"Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy","volume":"13","author":"Wu","year":"2025","journal-title":"Front Public Health"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320189","article-title":"Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis","volume":"20","author":"Zheng","year":"2025","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2013","DOI":"10.1002\/onco.13954","article-title":"First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: A U.S.-based cost-effectiveness analysis","volume":"26","author":"Lin","year":"2021","journal-title":"Oncologist"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1238009","article-title":"Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma","volume":"14","author":"Huang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067198","article-title":"Impacts of unifying urban and rural residents\u2019 medical insurance on the hospitalisation expenses of rural patients in eastern China: an interrupted time series analysis","volume":"13","author":"Qin","year":"2023","journal-title":"BMJ Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"31958","DOI":"10.1038\/s41598-024-83509-x","article-title":"First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis","volume":"14","author":"Long","year":"2024","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169752","article-title":"Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.880280","article-title":"Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"B37","unstructured":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:30:38Z","timestamp":1758605438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1658740"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658740","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1658740"}}